Recent news coverage primarily reports on investor ownership changes and ex-dividend dates, with no material new business developments disclosed.

• Mfp Investors acquired a 3.70% ownership stake in Gyrodyne [N1].
• Grantham, Mayo, Van Otterloo & Co. reduced its stake in Gyrodyne [N2].
• Gyrodyne had an ex-dividend date scheduled for June 16, 2016 [N3].
• Michael Price purchased shares in related companies, including Gyrodyne [N4].
• Michael Price's low P/E stock review included Gyrodyne [N5].
• Billionaire backers were noted on a shifting sea of 52-week lows including Gyrodyne [N6].
• Gyrodyne had an ex-dividend date scheduled for December 17, 2012 [N7].
• James Montier's short screen included Gyrodyne [N8].

The company’s focused strategy to enhance property values through entitlement efforts and pursue strategic sales could increase the aggregate value of its assets. Successful resolution of legal challenges and receipt of subdivision and site plan approvals may enable closing of significant sales agreements, such as the 49-acre Flowerfield parcel sale. Effective management of operating cash flow and lease renewals could support liquidity during the liquidation process. The company’s plan to modify loan facilities and manage capital prudently may provide operational stability through the liquidation timeline. These factors could contribute to maximizing distributions to shareholders upon dissolution.

Risks include delays or failure in obtaining necessary subdivision and site plan approvals, which are critical for closing sales transactions and generating liquidity. Ongoing legal proceedings pose uncertainties and potential costs. The company’s limited cash runway and operating losses during the liquidation process may pressure financial resources. Failure to secure loan modifications or new credit facilities could impair operations. Activist shareholder actions and proxy contests may disrupt management focus and strategic execution. Market conditions and tenant defaults could adversely affect rental income and asset values, reducing potential distributions to shareholders.

Gyrodyne’s moat is limited and primarily derives from its ownership of specific real estate assets in New York with potential for value enhancement through entitlement processes. The company’s strategy to increase development flexibility and lease value aims to maximize asset sale proceeds. However, the real estate market is competitive, and the company faces risks from regulatory approvals, legal challenges, and market conditions. Its liquidation status and limited operational scale reduce typical competitive advantages such as scale or brand. The moat is thus narrow and contingent on successful execution of entitlement and sale strategies.

• Regulatory and Legal Risks: The company faces ongoing legal challenges related to subdivision approvals for its Flowerfield property, including appeals and motions that may delay or impact the entitlement process and sales timeline.
• Approval and Timing Risks: Receipt of subdivision and site plan approvals is uncertain and may take years or may not be obtained, affecting the ability to close sales and generate liquidity.
• Liquidity and Operating Risks: Gyrodyne has limited cash resources with approximately 18 months of runway absent asset sales and expects to incur operating losses during the liquidation process.
• Financing Risks: The company intends to modify existing loan facilities to support operations through 2028 but faces uncertainty in securing favorable terms or any new credit facilities.
• Shareholder Activism Risks: Proxy contests and activist shareholder actions could disrupt operations, divert management attention, and impact strategic execution.
• Market and Tenant Risks: Tenant concentration and potential defaults, as well as market conditions, could adversely affect rental income and asset values.

• Gyrodyne, LLC is a limited liability company formed under New York law primarily managing a portfolio of medical office and industrial properties located in Suffolk (Flowerfield) and Westchester (Cortlandt Manor) Counties, New York [S1].
• The company’s business strategy focuses on enhancing the value of its Flowerfield and Cortlandt Manor properties by pursuing entitlement opportunities to increase development flexibility and by enhancing lease values [S1].
• Gyrodyne intends to dissolve after disposing of all real property assets, settling debts and claims, and distributing proceeds to common shareholders [S1].
• The company’s real estate portfolio includes 13.8 acres in Cortlandt Manor with a 31,000 square foot medical center and 63 acres in Flowerfield including a 14-acre multi-tenant industrial park with 135,000 rentable square feet [S1].
• Most developed properties are leased with tenants reimbursing the company for utilities, insurance, repairs, maintenance, and real estate taxes; some leases require the company to cover certain operating expenses [S1].
• The company is engaged in a legal proceeding (Article 78 Proceeding) challenging subdivision approvals for the Flowerfield property; the company is defending the approvals and the case is ongoing with appeals and motions [S1].
• Gyrodyne has entered into a Purchase and Sale Agreement for approximately 49 acres of Flowerfield property to B2K Smithtown LLC, contingent on subdivision and site plan approvals [S1].
• The company expects the liquidation process to extend through 2028, including entitlement efforts, sales, and legal proceedings [S1].
• As of December 31, 2025, Gyrodyne had cash and cash equivalents of approximately $4.53 million [S1].
• The company reported revenue of approximately $1.83 million and a net loss of approximately $2.5 million for the fiscal year ended August 31, 2015 [S1].
• Gyrodyne operates under a liquidation basis of accounting since September 1, 2015, reflecting the imminent liquidation plan [S1].
• Estimated net assets as of December 31, 2025 were approximately $25.86 million, implying estimated liquidating distributions of about $11.76 per common share based on 2,199,308 shares outstanding [S1].
• The company’s plan includes managing the real estate portfolio to improve operating cash flow, pursuing entitlements, managing strategic sales, focusing capital use to preserve or improve market value, and ensuring sufficient capital to operate through liquidation [S1].
• Gyrodyne has two loan facilities secured by the Flowerfield industrial park with outstanding balances of approximately $1.83 million and $2.5 million as of December 31, 2025, with maturities in 2028 [S1].
• The company intends to seek modifications to its loan facilities to strengthen its financial position through the end of 2028 [S1].
• Gyrodyne has limited cash runway and expects to incur operating losses while pursuing approvals and sales; it has approximately 18 months of cash to fund operations absent asset sales [S2].
• The company faces risks related to the timing and receipt of subdivision and site plan approvals, which are required for closing sales transactions [S2].
• Gyrodyne is subject to risks from proxy contests and activist shareholders; it entered into agreements with Star Equity Fund, LP to resolve nomination disputes and limit proxy contest risks [S2].
• The company’s three largest tenants accounted for approximately 26%, 19%, and 11% of rental income in 2025, including a medical tenant in Cortlandt Manor and a New York State agency in the industrial park [S1].
• Leasing activity in 2025 included signing four new leases totaling 5,676 square feet and terminating three leases totaling 4,471 square feet [S1].
• Recent news includes investor ownership changes and ex-dividend date announcements, with no material new business developments reported [N1][N2][N3].